ATE245164T1 - Rekombinanter papillomavirus l1 - Google Patents

Rekombinanter papillomavirus l1

Info

Publication number
ATE245164T1
ATE245164T1 AT95918467T AT95918467T ATE245164T1 AT E245164 T1 ATE245164 T1 AT E245164T1 AT 95918467 T AT95918467 T AT 95918467T AT 95918467 T AT95918467 T AT 95918467T AT E245164 T1 ATE245164 T1 AT E245164T1
Authority
AT
Austria
Prior art keywords
papilloma virus
protein
recombinant
vlp
recombinant papillomavirus
Prior art date
Application number
AT95918467T
Other languages
English (en)
Inventor
Ian Frazer
Jian Zhou
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE245164T1 publication Critical patent/ATE245164T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical
AT95918467T 1994-05-17 1995-05-17 Rekombinanter papillomavirus l1 ATE245164T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM5667A AUPM566794A0 (en) 1994-05-17 1994-05-17 Process and product
PCT/AU1995/000292 WO1995031476A1 (en) 1994-05-17 1995-05-17 Recombinant papilloma virus l1

Publications (1)

Publication Number Publication Date
ATE245164T1 true ATE245164T1 (de) 2003-08-15

Family

ID=3780242

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03006355T ATE340859T1 (de) 1994-05-17 1995-05-17 Rekombinantes papillomavirus l1 protein
AT95918467T ATE245164T1 (de) 1994-05-17 1995-05-17 Rekombinanter papillomavirus l1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03006355T ATE340859T1 (de) 1994-05-17 1995-05-17 Rekombinantes papillomavirus l1 protein

Country Status (13)

Country Link
US (1) US6013262A (de)
EP (2) EP1325957B1 (de)
JP (3) JPH10500295A (de)
KR (1) KR100384922B1 (de)
AT (2) ATE340859T1 (de)
AU (1) AUPM566794A0 (de)
CA (1) CA2190473C (de)
DE (2) DE69535249T2 (de)
DK (1) DK0759935T3 (de)
ES (2) ES2203640T3 (de)
NZ (1) NZ285339A (de)
PT (2) PT759935E (de)
WO (1) WO1995031476A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE69535018T2 (de) * 1994-05-16 2007-02-15 Merck & Co., Inc. Papillomavirus vakzine
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
SK138199A3 (en) * 1997-04-08 2000-06-12 Merck & Co Inc Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
EP1140161B1 (de) * 1998-12-17 2006-04-19 Merck & Co., Inc. Synthetische virus-ähnliche partikel mit heterologen epitopen.
US6689366B1 (en) 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
WO2000039151A1 (en) * 1998-12-23 2000-07-06 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
PT1150712E (pt) 1999-02-05 2008-12-22 Merck & Co Inc Formulações para a vacina do vírus do papiloma humano
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
AU2001275438A1 (en) * 2000-07-06 2002-01-21 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
WO2002009645A2 (en) * 2000-08-01 2002-02-07 The Johns Hopkins University Intercellular transport protein linked to an antigen as a molecular vaccine
WO2002012281A2 (en) * 2000-08-03 2002-02-14 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
AU2003213065A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Novel insect cell line
CA2497798A1 (en) 2002-09-03 2004-04-22 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
AU2005314061B2 (en) 2004-12-08 2010-01-28 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2595726A1 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
EP1877087B1 (de) * 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US20100003704A1 (en) * 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
EP2154147B1 (de) * 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gekürztes l1-protein des humanen papillomavirus 16
EP2154149B1 (de) * 2007-05-29 2019-07-10 Xiamen University Verkürztes l1-protein des humanen papillomavirus 6
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
JP2012526286A (ja) 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
EP2576840B1 (de) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Hybrid-capture-assay mit schneller ergebnislieferung und zugehörige strategisch gekürzte sonden
EP4141110A1 (de) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Verfahren zur herstellung von bakteriophagenteilchen der gattung levivirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (de) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Papillomavirus-Immunogene
JP3828570B2 (ja) * 1991-07-19 2006-10-04 ザ・ユニバーシティ・オブ・クイーンズランド パピローマウイルスワクチン
EP0647140B1 (de) * 1992-06-25 2007-12-12 Georgetown University Papillomavirus vakzine
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ATE492289T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln

Also Published As

Publication number Publication date
DK0759935T3 (da) 2003-11-10
NZ285339A (en) 1998-04-27
WO1995031476A1 (en) 1995-11-23
EP0759935A4 (de) 1999-07-07
CA2190473C (en) 2011-08-30
JPH10500295A (ja) 1998-01-13
ES2275965T3 (es) 2007-06-16
EP1325957A3 (de) 2003-11-26
JP2006321806A (ja) 2006-11-30
DE69535249D1 (de) 2006-11-09
EP0759935A1 (de) 1997-03-05
KR100384922B1 (ko) 2003-08-21
DE69531297T2 (de) 2004-05-27
CA2190473A1 (en) 1995-11-23
JP4016054B2 (ja) 2007-12-05
EP1325957B1 (de) 2006-09-27
AUPM566794A0 (en) 1994-06-09
DE69535249T2 (de) 2007-05-10
US6013262A (en) 2000-01-11
EP0759935B1 (de) 2003-07-16
JP2006001936A (ja) 2006-01-05
ATE340859T1 (de) 2006-10-15
PT1325957E (pt) 2007-01-31
PT759935E (pt) 2003-11-28
JP3878197B2 (ja) 2007-02-07
EP1325957A2 (de) 2003-07-09
DE69531297D1 (de) 2003-08-21
ES2203640T3 (es) 2004-04-16

Similar Documents

Publication Publication Date Title
ATE245164T1 (de) Rekombinanter papillomavirus l1
NO20000850D0 (no) Vaksine
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
WO1999033868A3 (en) Human papillomavirus vaccine
DE69535018D1 (de) Papillomavirus vakzine
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ATE433491T1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
FR2697022B1 (fr) Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
DE69123970T2 (de) Ehv-4 glykoprotein vazin
FI113621B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
NL300336I1 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
ATE530563T1 (de) Rekombinante proteine einer pakistanischen hepatitis e variante und ihre verwendung in diagnoseverfahren und impfungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0759935

Country of ref document: EP